Regencell Bioscience Holdings Limited
RGC
$13.36
$1.028.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | 06/30/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.89% | -30.89% | -21.82% | -12.13% | -12.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.09% | -26.09% | -14.75% | -32.59% | -32.59% |
| Operating Income | 26.09% | 26.09% | 14.75% | 32.59% | 32.59% |
| Income Before Tax | 20.52% | 20.52% | 20.74% | 34.07% | 34.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.52% | 20.52% | 20.74% | 34.07% | 34.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -155.90% | 35.76% | 35.76% |
| Net Income | 22.58% | 22.58% | 15.46% | 35.97% | 35.97% |
| EBIT | 26.09% | 26.09% | 14.75% | 32.59% | 32.59% |
| EBITDA | 22.83% | 28.05% | 15.78% | 35.45% | 35.45% |
| EPS Basic | 26.09% | 26.09% | 14.81% | 36.36% | 36.36% |
| Normalized Basic EPS | 29.41% | 29.41% | 5.56% | -- | -- |
| EPS Diluted | 26.09% | 26.09% | 14.81% | 36.36% | 36.36% |
| Normalized Diluted EPS | 29.41% | 29.41% | 5.56% | -- | -- |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |